The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom

References

• Bodger K, Yen L, Szende A, et al. Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: a chart review analysis. Eur J Gastroenterol Hepatol. 2014;26(2):213–221.
   PubMed Web of Science ®Google Scholar
• Brookes MJ, Waller J, Cappelleri JC, et al. Living with ulcerative colitis study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol. 2020;7(1):e000456.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Tarallo M, Lucas J, et al. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol. 2020;20(1):1–11.
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Ulcerative colitis: management. NICE clinical guideline. London: NICE; 2019.
   Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68 (Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Danese S, Allez M, Van Bodegraven AA, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis. 2019;37(4):266–283.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–1291.
   PubMed Web of Science ®Google Scholar
• Plevris N, Chuah CS, Allen RM, et al. Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the scottish vedolizumab cohort. J Crohns Colitis. 2019;13(9):1111–1120.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the Cross Pennine study. Dig Liver Dis. 2018;50(12):1299–1304.
   PubMedGoogle Scholar
• Black CM, Yu E, McCann E, et al. Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data. PLOS One. 2016;11(2):e0149692.
   PubMed Web of Science ®Google Scholar
• Merrick VM, Mortier K, Williams LJ, et al. Real-life anti-tumor necrosis factor experience in more than 500 patients: high co-immunosuppression rates but low rates of quantifying treatment response. J Pediatr Gastroenterol Nutr. 2018;66(2):274–280.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-I patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Patel H, Shi S, et al. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn’s disease in the United States: a claims data analysis. Curr Med Res Opin. 2017;33(3):529–536.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bernstein CN, Benchimol EI, et al. Trends in corticosteroid use during the era of biologic therapy: a population-based analysis. Am J Gastroenterol. 2021;116(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666.
   PubMed Web of Science ®Google Scholar
• Sebastian S, Roberts J, Waller J, et al. Remote monitoring of patient-reported outcomes in ulcerative colitis: a prospective real-world pilot study. Pharmacoecon Open. 2019;3(3):359–365.
   PubMed Web of Science ®Google Scholar
• Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385–1393.
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Armuzzi A, Gisbert JP, et al. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017;49(10):1086–1091.
   PubMedGoogle Scholar
• Hoque S, Puenpatom A, Boccaletti S, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020;7(1):e000476.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, DiBonaventura M da C, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLOS One. 2020;15(1):e0227914.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Parkes GC, Bassi A, et al. Assessment of steroid use as a key performance indicator in inflammatory bowel disease—analysis of data from 2385 UK patients. Aliment Pharmacol Ther. 2019;50(9):1009–1018.
   PubMed Web of Science ®Google Scholar